The last 5 years have witnessed relevant advances in the systemic treatment of hepatocellular carcinoma. New data have emerged since the development of the EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma in 2018. Drugs licensed in some countries now include 4 oral multi-tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib), 1 anti-angiogenic

Nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of developing hepatocellular carcinoma (HCC) especially among those who have cirrhosis or advanced fibrosis but 20-30% of NAFLD related HCC occur in the absence of advanced fibrosis. The prevalence of NAFLD-related HCC is increasing in most countries worldwide. There are few direct data to support or refute the efficacy or

Background & Aims SORAMIC is a previously published randomized controlled trial assessing survival in patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib with or without selective internal radiation therapy (SIRT). Based on the per-protocol population (PP), we assessed whether the outcome of patients receiving SIRT+sorafenib vs. sorafenib alone was affected by adverse effects

NAFLD is projected to become the leading cause of HCC in many countries. Many risk factors for NAFLD are also independently associated with HCC, including obesity, diabetes, Hispanic ethnicity and genetic polymorphisms in PNPLA3, TM6SF2, GCKR, MBOAT7 and HSD17B13. Steatosis-related lipotoxicity and oxidative DNA damage can induce hepatocarcinogenesis. These factors may explain the association between

Hepatic encephalopathy (HE) is a complication of cirrhosis characterized by neuropsychiatric and motor dysfunction. Microbiota-host interactions have an important role in HE pathogenesis. Therapies targeting microbial community composition and function have been explored for the treatment of HE. Prebiotics, probiotics and fecal microbiota transplant (FMT) have aimed to increase the abundance of potentially

Humans harbor a large quantity of microbes in the intestinal tract and have evolved symbiotic relationships with many of them. Several specific bacterial pathobionts have been associated with liver disease pathogenesis. Although bacteriophages (phages) and eukaryotic viruses (collectively known as “the virome”) outnumber bacteria and fungi in the intestine, little is known about the intestinal virome

Non-invasive tests are increasingly being used to improve the diagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis, focusing on the topics for which relevant evidence has been published in the last 5 years.

The Fibroblast growth factor (FGF) receptor 4 (FGFR4) and its cognate ligand, FGF19 are implicated in an ample range of cellular processes, including differentiation, metabolism and proliferation. Their aberrant activation has been associated to the development of hepatic tumours, acting as an oncogenic pathway. Despite the great advances in early diagnosis, and the development of new therapies, liver

In many countries worldwide, the burden of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing and preventive strategies are needed to counteract this trend. This review provides an overview of the evidence on preventive strategies in NAFLD-associated HCC. We considered the impact of lifestyle factors such as weight loss

Antibody-mediated rejection after liver transplantation is an under-recognized cause of allograft injury. While definitions of acute and chronic antibody-mediated rejection have increased clinical awareness, timely identification and management of antibody-mediated rejection remain difficult due to complexities in diagnosis and histopathology, lack of treatment protocols, and unclear long-term outcomes